Rising cash flows put HTHT, BTSG, REPX and MG on watch as estimates climb and businesses expand in hospitality, care, energy and testing.
If you are looking for stocks that are well positioned to maintain their recent uptrend, BrightSpring Health Services, Inc. (BTSG) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
BrightSpring Health Services, Inc. (BTSG) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Let's take a look at four stocks, RELY, MG, BTSG and CSTM, with stellar net profit margins and rising EPS estimates that can help create a winning portfolio.
Investors interested in Medical Services stocks are likely familiar with BrightSpring Health Services, Inc. (BTSG) and Alignment Healthcare (ALHC). But which of these two stocks presents investors with the better value opportunity right now?
Phibro Animal Health, Deluxe, Remitly Global and BrightSpring Health Services, Inc. (BTSG) represent four compelling small-cap stocks.
The consensus price target hints at a 25.5% upside potential for BrightSpring Health Services, Inc. (BTSG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, BrightSpring Health Services, Inc. (BTSG) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BTSG leans on specialty and provider growth in 2026, with margin expansion expected to outpace revenue despite near-term pharmacy headwinds.
BTSG trades at 24.5x forward earnings after strong 2025 results, but 2026 hinges on margin gains offsetting policy-driven revenue headwinds.